Results 211 to 220 of about 5,926,898 (305)

The return to work after arthroplasty (REWARD) cohort: a nationwide longitudinal study of sick leave and disability pension among individuals receiving hip and knee arthroplasty in Sweden. [PDF]

BMJ Open
Gustafsson K, Liv P, Rolfson O, Kuijer PPFM, Mukka S, Wahlström J.   +5 more
europepmc   +1 more source

State regulation of the compulsory medical system insurance in Azerbaijan

CONFERENCE MATERIALS, 2019
openaire   +1 more source

Do Patients Value the Service Provided by Physicians Who Overbill? A Willingness-to-Pay Study Using French Survey Data. [PDF]

Health Econ
Lamiraud K, Vranceanu R.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Medical Care Insurance: Lessons from Voluntary and Compulsory Plans

American Journal of Public Health and the Nations Health, 1951
openaire   +6 more sources

RISE for recovery after acute whiplash injury: protocol for a randomised feasibility trial of a clinician-supported SMS-based behavioural intervention. [PDF]

BMJ Open
Elphinston RA, Formosa J, Armfield N, van der Vegt AH, Ashton-James CE, Brain K, Buckley L, Papic C, Khan A, Eather CE, Liimatainen J, Hobbins King A, Hansen K, Staib A, Smith GM, Chen T, Wright K, Garrad E, Sterling M.   +18 more
europepmc   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer, Eliza J. McEwin, Zhicheng Wang, Joel Lexchin, Barbara Mintzes   +4 more
wiley   +1 more source